Modeling Clinical Outcomes in Gambling Addiction (MOGADOR)

Civil Hospices of Lyon

Status: Not yet enrolling

Conditions: Gambling Disorder

Study type: Observational

Funder types: Other

Identifiers

NCT06981546

2024-A01805-42 (Other Identifier)

69HCL21_0270

Details and patient eligibility

About

Gambling disorder (GD) is recognized as an addictive disorder. Financial consequences of GD are often dramatic, inducing professional, familial, legal and medical repercussions and particularly mental health consequences.

MOGADOR is a longitudinal, multicentric, prospective, prognostic study, which aims to identify factors predicting the evolution of french patients with GD in care centers particularly involved in the management of GD. The main goal will focus on evolution of DSM-5 (Diagnostic and Statistical Manual of Mental Disorder 5th edition) GD criteria during the first year of follow-up. The prognostic factors will be collected at base-line and they will be considered to influence the long-term prognosis of patients.

For patients suffering of GD, our main hypothesis is that initial factors like individual socio-demographic characteristics, clinical psychiatric profiles, addiction comorbidities, and behaviour are associated with the clinical prognosis (total remission of DSM-5 criteria of GD at 12 months).

MOGADOR will be the first study, aiming to model prognostic aspects of GB in populations specially monitored for this disorder.

Enrollment: 268 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient, male or female, over 18 years old, consulting in one of the participating centers.
• DSM-5 criteria for gambling disorder at inclusion: at least 4 criteria present in the 12 months preceding the study.
• First treatment for gambling disorder or no treatment in the last 6 months (initiation or re-initiation of care).

Exclusion criteria

• Unable to be reached by phone.
• Unable to use the internet.
• Patient under antiparkinsonian treatment of the dopaminergic family.
• Being treated with a drug that may trigger/increase symptoms of gambling disorder (e.g. dopamine agonist).
• Subject under guardianship.

Trial design

268 participants in 1 patient group

Patients with gambling disorder

Description:

OGADOR will focus exclusively on patients with DSM-5 criteria for gambling disorder and on demand for medical care. In this study psychiatric and addictological comorbidities, frequent in such a cohort, will constitute a specific inclusion factor, key characteristic leading an analysis of the impact on the patient prognosis.